指南与共识妇产科病理细胞病理与分子病理

卵巢癌同源重组缺陷检测的系统分析及优化检测性能的建议

Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
指南 / 共识 · Mod Pathol · 2024-02-08

该研究系统分析了2702例真实世界卵巢癌样本的HRD检测组织参数,发现肿瘤细胞含量、肿瘤面积和组织学类型显著影响检测成功率。基于分析,推荐选择肿瘤细胞含量≥30%且肿瘤面积≥0.5 cm²的高级别浆液性卵巢癌样本进行HRD检测,可使成功率高达98%。

要点

  • 推荐高级别浆液性卵巢癌样本肿瘤细胞含量≥30%且肿瘤面积≥0.5 cm²用于HRD检测。
  • 肿瘤细胞含量、面积和组织学类型显著影响HRD检测成功率(P<.0001)。
  • 符合条件样本的HRD检测成功率可达98%。

核心结论

  • 推荐选择肿瘤细胞含量≥30%且肿瘤面积≥0.5 cm²的高级别浆液性卵巢癌样本进行HRD检测,以最大化成功率和结论可靠性。

主要发现

  • 2654例样本中2396例(90.3%)成功检测,其中984例(41.1%)为HRD阳性,1412例(58.9%)为HRD阴性。
  • BRCA1/2突变样本的GIS值显著高于BRCA1/2野生型样本(P<.0001)。
  • 肿瘤细胞含量、肿瘤面积和组织学类型均显著影响样本成功分析的概率(P<.0001)。

关键数值与推荐

  • 推荐选择肿瘤细胞含量≥30%且肿瘤面积≥0.5 cm²(基于H&E染色)的高级别浆液性卵巢癌样本进行HRD检测。
  • 考虑组织学和样本条件,HRD检测成功率可达98%。

临床怎么用

  • 病理科医生和妇科肿瘤医生应依据肿瘤细胞含量≥30%和肿瘤面积≥0.5 cm²的标准选择卵巢癌样本送检HRD,以提高检测成功率和个性化治疗决策质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Homologous recombination deficiency (HRD) assays are an important element of personalized oncology in ovarian carcinomas, but the optimal tissue requirements for these complex molecular assays remain unclear. As a result, a considerable percentage of assays are not successful, leading to suboptimal diagnoses for these patients. In this study, we have systematically analyzed tumor and tissue parameters for HRD analysis in a large cohort of real-world cancer samples. The aim of this study is to give recommendations for pathologists and gynecologic oncologists for selection of tissue samples to maximize the success rate of HRD analyses. Tumor samples from 2702 patients were sent to the Institute of Pathology of the Philipps-University Marburg between October 2020 and September 2022, of which 2654 were analyzed using the Myriad MyChoice HRD+ CDx assay. A total of 2396 of 2654 samples (90.3%) were successfully tested, of which 984 of 2396 (41.1%) were HRD positive and 1412 (58.9%) were HRD negative. Three hundred sixty-three of 2396 samples (15.2%) were BRCA1/2-mutated; 27 samples had a BRCA1/2 mutation and a genomic instability score (GIS) < 42. Twenty-two samples (0.9%) failed GIS measurement but displayed a BRCA1/2 mutation. BRCA1/2-mutated samples showed significantly (P < .0001) higher GIS values than those with a wild-type BRCA1/2 status. Tumor cell content, tumor area, and histology significantly (P < .0001) affected the probability of successfully analyzing a sample. Based on a systematic analysis of tumor cell content and tumor area, we recommend selecting patient high-grade serous ovarian cancer samples that display a tumor cell content ≥30% and a tumor area ≥0.5 cm2 (based on their hematoxylin and eosin) for HRD testing to allow for optimal chances of a successful analysis and conclusive results. Considering histologic and sample conditions, success rates of up to 98% can be achieved. Our comprehensive evaluation contributes to further standardization of recommendations on HRD testing in ovarian cancer, which will have a large impact on personalized therapeutic strategies in this highly aggressive tumor type.

来源:Mod Pathol,查看原文。版权归原作者所有。

引用

  1. Romey M, Rodepeter F, Hattesohl A, et al. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance. Mod Pathol. 2024. PMID: 38341130. doi:10.1016/j.modpat.2024.100445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。